BOSTON, Sept. 24, 2014 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity, today announced that Thomas Hughes, Ph.D., Chief Executive Officer, is scheduled to present a company overview at the 2014 Leerink Partners Rare Disease Roundtable. The conference is being held on October 1, 2014 at the Le Parker Meridien Hotel in New York City. Zafgen is scheduled to present at 11:05 a.m. ET. A live webcast of the presentation will be available on Zafgen's website, www.zafgen.com.
Zafgen (Nasdaq:ZFGN) is a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic disorders. Zafgen is focused on developing novel therapeutics that treat the underlying biological mechanisms through the MetAP2 pathway. Beloranib, Zafgen's lead product candidate, is a novel, first-in-class, twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in two rare diseases, Prader-Willi syndrome and obesity caused by hypothalamic injury, including craniopharyngioma-associated obesity; and severe obesity in the general population.Zafgen aspires to improve the lives of patients through targeted treatments and has assembled a team accomplished in bringing therapies to patients with both rare and prevalent metabolic diseases.
CONTACT: FTI Consulting Brian Ritchie Investor Relations (212) 850-5683 Brian.Ritchie@fticonsulting.comSource:Zafgen, Inc.